Table 1.
Baseline characteristics between the transarterial chemoembolization (TACE) and hepatic resection (HR) groups in the derivation cohort.
| Treatment | p-value | ||
|---|---|---|---|
| TACE (n = 717) | HR (n = 225) | ||
| Age (years) | 53.9 ± 12.3 | 50.9 ± 12.6 | 0.001 |
| Gender | 0.802 | ||
| Male | 654 (91.2%) | 204 (90.7%) | |
| Female | 63 (8.8%) | 21 (9.3%) | |
| HBV infection | 0.132* | ||
| No | 18 (2.8%) | 2 (1.0%) | |
| Yes | 622 (97.2%) | 203 (99.0%) | |
| Child–Pugh class | 0.302 | ||
| A | 613 (85.5%) | 186 (82.7%) | |
| B | 104 (14.5%) | 39 (17.3%) | |
| Diameter of main tumor (cm) | 7. 5 ± 3.8 | 6.4 ± 2.8 | <0.001 |
| Location of lesions | <0.001 | ||
| Unilobar | 254 (35.4%) | 148 (65.8%) | |
| Bilobar | 463 (64.6%) | 77 (34.2%) | |
| Intrahepatic tumor number | <0.001 | ||
| ≤3 | 237 (33.1%) | 142 (63.1%) | |
| >3 | 480 (66.9%) | 83 (36.9%) | |
| AFP (ng/ml) | 0.014 | ||
| <25 | 180 (26.5%) | 75 (35.2%) | |
| ≥25 | 500 (73.5%) | 138 (64.8%) | |
| CRP (mg/L) | <0.001 | ||
| <10 | 318 (45.4%) | 72 (32.4%) | |
| ≥10 | 382 (54.6%) | 150 (67.6%) | |
| Hgb (g/L) | <0.001 | ||
| <120 | 148 (20.8%) | 71 (31.6%) | |
| ≥120 | 562 (79.2%) | 154 (68.4%) | |
| LDH (U/L) | <0.001 | ||
| <245 | 356 (50.1%) | 152 (67.6%) | |
| ≥245 | 354 (49.9%) | 73 (32.4%) | |
| WBC (109/L) | <0.001 | ||
| <11 | 611 (86.9%) | 162 (74.0%) | |
| ≥11 | 92 (13.1%) | 57 (26.0%) | |
| PLT (109/L) | 0.249 | ||
| <150 | 381 (53.7%) | 111 (49.3%) | |
| ≥150 | 328 (46.3%) | 114 (50.7%) | |
Numbers that do not add up to 942 are attributable to missing data. Chi-square test was performed for categorical measures and the Kruskal–Wallis test for continuous measures.
HBV, hepatitis B virus; AFP, alpha-fetoprotein; CRP, C-reactive protein; Hgb, hemoglobin; LDH, lactate dehydrogenase; WBC, white blood cell; PLT, platelet.
*Fisher’s exact probability test.